

Box 1. American Joint Cancer Committee/Union for International Cancer Control 7th edition  
TNM staging for intrahepatic cholangiocarcinoma

**Primary tumor (T)c:**

- TX Primary tumor cannot be assessed
- T0 No evidence of primary tumor
- Tis Carcinoma *in situ* (intraductal tumor)
- T1 Solitary tumor without vascular invasion
- T2a Solitary tumor with vascular invasion
- T2b Multiple tumors, with or without vascular invasion
- T3 Tumors perforating the visceral peritoneum OR involving local hepatic structures by direct invasion
- T4 Tumor with periductal invasion

**Regional lymph nodes (N):**

- NX Regional lymph nodes cannot be assessed
- N0 No regional lymph node metastases
- N1 Regional lymph node metastases present

**Distant metastases (M):**

- M0 No distant metastases
- M1 Distant metastases present

**Anatomic stage/prognostic groups:**

Stage 0	Tis	N0	M0
Stage I	T1	N0	M0
Stage II	T2	N0	M0
Stage III	T3	N0	M0
Stage IVA	T4	N0	M0
	Any T	N1	M0
Stage IVB	Any T	Any N	M1

Permission obtained from Wiley-Blackwell © Sobin, L. H. *et al.* (Eds) TNM Classification of Malignant Tumours, 7th Edition (Wiley-Blackwell, Oxford, 2009).

Box 2. Liver Cancer Study Group of Japan (LCSGJ) staging system for intrahepatic cholangiocarcinoma

**Prognostic criteria:**

- 1 Tumor size  $\leq 2$ cm
- 2 Tumor number: 1
- 3 No portal vein, hepatic vein or serosal invasion

- T1 All three criteria  
T2 Two of three criteria  
T3 One of three criteria  
T4 None of three criteria

- N0 No lymph node metastases  
N1 Lymph node metastases

- M0 No distant metastases  
M1 Distant metastases

- Stage I T1N0M0  
Stage II T2N0M0  
Stage III T3N0M0  
Stage IVA T4N0M0  
Stage IVB Any T, any NM

Permission obtained from Springer © Yamasaki, S. *J. Hepatobiliary Pancreat. Surg.* 10, 288–291 (2003).

Box 3. National Cancer Center in Japan (NCCJ) staging system for mass-forming intrahepatic cholangiocarcinoma

**Primary tumor (T):**

- T1 Solitary tumor without vascular invasion
- T2 Solitary tumor with vascular invasion
- T2 Multiple tumors with or without vascular invasion

**Regional lymph nodes (N):**

- N0 No regional lymph node metastases
- N1 Regional lymph node metastases

**Distant metastases (M):**

- M0 No distant metastases
- M1 Distant metastases present

**Stage grouping:**

Stage I	T1	N0	M0
Stage II	T2	N0	M0
Stage IIIA	T3	N0	M0
Stage IIIB	Any T	N1	M0
Stage IV	Any T	Any N	M1

Permission obtained from John Wiley and Sons © Okabayashi, T. *et al. Cancer* **92**, 2374–2383 (2001).

Box 4. American Joint Cancer Committee/Union for International Cancer Control 7th edition TNM staging for perihilar cholangiocarcinoma

**Primary tumor (T)c:**

- Tx Primary tumor cannot be assessed
- T0 No evidence of primary tumor
- Tis Carcinoma *in situ*
- T1 Tumor confined to the bile duct, with extension up to the muscle layer or fibrous tissue
- T2A Tumor invades beyond the wall of the bile duct to surrounding adipose tissue
- T2B Tumor invades adjacent hepatic parenchyma
- T3 Tumor invades unilateral branches of the portal vein or hepatic artery
- T4 Tumor invades main portal vein or its branches bilaterally; or the common hepatic artery; or the second-order biliary radical bilaterally; or unilateral second order biliary radicals with contralateral portal vein or hepatic artery involvement

**Regional lymph nodes (N):**

- NX Regional lymph nodes cannot be assessed
- N0 No regional lymph node metastases
- N1 Regional lymph node metastases present (including nodes along the cystic duct, common bile duct, hepatic artery, and portal vein)
- N2 Metastases to periaortic, pericaval, superior mesenteric artery, and/or celiac artery lymph nodes

**Distant metastases (M):**

- M0 No distant metastases
- M1 Distant metastases present

**Anatomic stage/prognostic groups:**

Stage 0	Tis	N0	M0
Stage I	T1	N0	M0
Stage II	T2A-B	N0	M0
Stage IIIA	T3	N0	M0
Stage IIIB	T1-3	N1	M0
Stage IVA	T4	N0-1	M0
Stage IVB	Any T	N2	M0
	Any T	Any N	M1

Box 5. American Joint Cancer Committee/Union for International Cancer Control 7th edition  
TNM staging for distal extrahepatic cholangiocarcinoma

**Primary tumor (T)c:**

- TX Primary tumor cannot be assessed
- T0 No evidence of primary tumor
- Tis Carcinoma *in situ*
- T1 Tumor confined to the bile duct histologically
- T2 Tumor invades beyond the wall of the bile duct
- T3 Tumor invades the gallbladder, pancreas, duodenum, or other adjacent organs without involvement of the celiac axis, or the superior mesenteric artery
- T4 Tumor involves the celiac axis, or the superior mesenteric artery

**Regional lymph nodes (N):**

- NX Regional lymph nodes cannot be assessed
- N0 No regional lymph node metastases
- N1 Regional lymph node metastases present

**Distant metastases:**

- M0 No distant metastases
- M1 Distant metastases present

**Anatomic stage/prognostic group**

Stage 0	Tis	N0	M0
Stage IA	T1	N0	M0
Stage IB	T2	N0	M0
Stage IIA	T3	N0	M0
Stage IIB	T1	N1	M0
	T2	N1	M0
	T3	N1	M0
Stage III	T4	Any N	M0
Stage IV	Any T	Any N	M1

Permission obtained from Wiley-Blackwell © Sobin, L. H. et al. (Eds) TNM Classification of Malignant Tumours, 7th Edition (Wiley-Blackwell, Oxford, 2009).

Table 1. Memorial Sloan-Kettering Cancer Center staging system for hilar cholangiocarcinoma	
Stage	Criteria
T1	Tumor involving biliary confluence +/- unilateral extension to second-degree biliary radicles
T2	Tumor involving biliary confluence +/- unilateral extension to second-degree biliary radicles AND Ipsilateral portal vein involvement +/- ipsilateral hepatic lobe atrophy
T3	Tumor involving biliary confluence +/- unilateral extension to second-degree biliary radicles OR Unilateral extension to second-degree biliary radicles with contralateral portal vein involvement OR Unilateral extension to second-degree biliary radicles with contralateral hepatic lobe atrophy OR Main or bilateral portal venous involvement
Permission obtained from Lippincott Williams and Wilkins © Jarnagin, W. R. <i>et al. Ann. Surg.</i> 234, 507–517 (2001).	

Table 2. Proposed clinical staging system for perihilar cholangiocarcinoma				
Criteria	Stage			
	Stage I	Stage II	Stage III	Stage IV
<i>Mass lesions</i>	None	Unicentric $\leq 3$ cm	Unicentric $>3$ cm	Multicentric
<i>Metastases</i>	None	None	Perihilar LN	Perihilar LN
<i>Lobar atrophy and/or vascular encasement</i>	No	Yes	NA	NA
<i>Jaundice resolution with stenting</i>	Yes	Yes	No	NA
<i>ECOG performance status</i>	0-1	0-1	0-1	$\geq 2$

Abbreviations: ECOG, Eastern Cooperative Oncology Group; LN, lymph node; NA, not applicable. Permission obtained from Lippincott Williams and Wilkins © Blechacz, B. R. *et al.* *Curr. Opin. Gastroenterol.* **25**, 238–239 (2009).

Table 3. Proposed staging system by Deoliveira <i>et al.</i>		
<b>und</b>	<b>Side/location</b>	<b>Description</b>
		<b>Bile duct (B) (Based on Bismuth Classification)</b>
B1		Common bile duct
B2		Hepatic duct confluence
B3	R	Right hepatic duct
B3	L	Left hepatic duct
B4		Right and left hepatic duct
		<b>Tumor size (T)</b>
T1		< 1cm
T2		1 - < 3 cm
T3		≥ 3cm
		<b>Tumor Form (F)</b>
Scerosing		Scerosing (or periductal)
Mass		Mass forming (or nodular)
Mixed		Scerosing and mass forming
Polipoid		Polipoid (or intraductal)
		<b>Involvement (&gt;180°) of the portal vein (PV)</b>
PV0		No portal involvement
PV1		Main Portal vein
PV2		Portal vein bifurcation
PV3	R	Right portal vein
PV3	L	Left portal vein
PV4		Right and left portal vein
		<b>Involvement (&gt;180°) of the hepatic artery (HA)</b>
HA0		No arterial involvement
HA1		Proper hepatic artery
HA2		Hepatic artery bifurcation
HA3	R	Right hepatic artery
HA3	L	Left hepatic artery
HA4		Right and left hepatic artery
		<b>Liver remnant volume (V)</b>
V 0		No information on volume needed (liver resection not foreseen)
V (%)	Indicate segments	% total volume of a putative remnant liver after resection
		<b>Lymph Nodes (N) (based on Japanese Society of Biliary Surgery)</b>
N0		No lymph nodes involvement
N1		Hilar and/or hepatic artery lymph nodes involvement
N2		Peri-aortic lymph nodes involvement
		<b>Metastases (M) ( Based on TNM classification(11))</b>
M0		No distant metastases
M1		Distant metastases, including liver and peritoneal metastases
Permission obtained from John Wiley and Sons© Deoliveira, M. L. <i>et al. Hepatology</i> <b>53</b> , 1262–1371 (2011).		